Search: FDA – Page 6

So, your Stability Program is underway and/or flourishing. You’re focused on protocols, samples, chambers, disaster planning, testing, data analysis and reports—Each one gobbling up resources. You may happily have those resources in place, but [...]

This conference is about mastering stability testing, analytical methods, and QC excellence. Analytical and stability excellence form the cornerstone of product quality and Laboratory University 2026 unites both under one comprehensive program. With two full [...]

Hollister Incorporated, a global, employee-owned healthcare manufacturer, began a critical modernization initiative to overhaul its stability program. For years, Hollister had relied on traditional, paper-based systems to manage complex stability studies supporting the development [...]

It happens. Your stability chamber malfunctions or quits altogether and your product’s target exposure range has a significant deviation: too hot, too cold, too wet; too dry, OR, a fallible human placed the samples [...]

Registration is now open for Spring 2026 Pharmaceutical Stability Discussion Group meeting. We’ll meet in person with stabilitarians, stability stakeholders, consultants, and suppliers from all aspects of the medical product stability community. The program includes [...]

One of the most intelligent moves I’ve seen a corporate Stability organization make was the establishment of a Stability Intelligence (SI) Specialist within its ranks. Someone whose primary responsibility was to continuously monitor the [...]

Including an overview of ICH Guideline for Extractables and Leachables (Q3E), Step 2 Guideline--Don't miss your opportunity for public comment! This two-day conference will examine the safety, quality, and regulatory issues involved in a wide [...]

After decades of watching the ICH Stability-related Guidances grow and even stagnate, a major initiative to consolidate, expand, clarify and become more relevant to the users has just come through an industry-wide review and [...]

The presence of traces of N-Nitrosamine impurities in pharmaceutical products was first noted around 2018 in some sartans, particularly sartans that contained a tetrazole ring in their chemical structure and specifically Valsartan. It soon became [...]

Disasters occur whether we plan for them or not, but planning ahead to mitigate their impact and recover from their damage can make a big difference in corporate success. While we can’t control the nature [...]